
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Although outbursts of lethal violence in Iraq, Israel, and Afghanistan last month continue to threaten the peace of the world, attention in the nation's capital focused on domestic concerns.






